Penumbra names Thomas Wilder to its board
Mr. Wilder has over 30 years of experience, having most recently led Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies, as its CEO for the past six years.
Prior to joining Sequent, Mr. Wilder served as the President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients.
Prior to this, Mr. Wilder served as the President and CEO of MicroTherapeutics, Inc., a company also focused on the neurovascular space.
In addition, he served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division.
Mr. Wilder began his career in the Financial Statement Audit Practice of Price Waterhouse, where he worked from 1986 to 1989.
He currently serves on the Board of Directors of Benvenue Medical, Inc. and Endologix, Inc. .
In connection with Mr. Wilder's appointment, Walter Wang (Wang Ventures) is stepping down from the Board of Directors of Penumbra, where he serves on the Audit and Executive Committees and as chair of the Compensation Committee.
His resignation is effective January 13, 2017.